PF329: ER hydromorphone prodrug
Early-stage clinical trials were conducted with PF329, an extended-release prodrug of hydromorphone.
In two phase 1 studies, PF329 has demonstrated excellent safety, dose proportionality, and a clinically beneficial extended release profile.
A Fast Fed study showed little effect on activation of PF329 or its pharmacokinetic profile.
Fisher et al, First-in-man evaluation of PF329, an abuse-resistant prodrug of hydromorphone. Journal of Pain 2012;13(4): S76